Although COVID-19 primarily manifests as a lung infection with a wide spectrum of symptoms ranging from a mild upper respiratory illness to severe pneumonia and acute respiratory distress syndrome (ARDS), kidney involvement is common among patients with COVID-19, characterized by urinary abnormalities (proteinuria and haematuria reported in about 40% of cases). In addition, COVID-19 mainly affects patients with pre-existing comorbidities, such as patients with chronic kidney disease (CKD) and patients in chronic haemodialysis. Acute kidney injury (AKI) affects nearly 10-40% of critically ill patients admitted to ICUs with COVID-19 and significantly impacts on disease severity and outcomes. Renal replacement therapy (RRT) is required in approximately 20% of patients developing AKI.
This Research Topic aims to highlight current advances made in the understanding of molecular mechanisms and pathology of kidney disease in patients with SARS-CoV-2. Furthermore, it will attempt to cover the epidemiological aspect of renal dysfunction, including the incidence of Covid-associated AKI, urinary abnormalities and risk factors for AKI in critically ill patients. In addition, this collection proposes to characterize the current approaches of RRT and other extracorporeal treatments for patients with SARS-CoV-2.
We welcome submissions of Original Research, Case Report, Commentary, Opinion, and Review articles. Specifically, themes of interest include but are not limited to:
• Experimental studies about mechanisms of Covid-19 induced renal damage
• Epidemiology of AKI
• Determination of risk factors for AKI in specific population (chronic haemodialysis, peritoneal dialysis, kidney transplant recipients)
• Extracorporeal therapies protocols for critically ill patients
• Long-term sequelae from COVID-19 infections
Although COVID-19 primarily manifests as a lung infection with a wide spectrum of symptoms ranging from a mild upper respiratory illness to severe pneumonia and acute respiratory distress syndrome (ARDS), kidney involvement is common among patients with COVID-19, characterized by urinary abnormalities (proteinuria and haematuria reported in about 40% of cases). In addition, COVID-19 mainly affects patients with pre-existing comorbidities, such as patients with chronic kidney disease (CKD) and patients in chronic haemodialysis. Acute kidney injury (AKI) affects nearly 10-40% of critically ill patients admitted to ICUs with COVID-19 and significantly impacts on disease severity and outcomes. Renal replacement therapy (RRT) is required in approximately 20% of patients developing AKI.
This Research Topic aims to highlight current advances made in the understanding of molecular mechanisms and pathology of kidney disease in patients with SARS-CoV-2. Furthermore, it will attempt to cover the epidemiological aspect of renal dysfunction, including the incidence of Covid-associated AKI, urinary abnormalities and risk factors for AKI in critically ill patients. In addition, this collection proposes to characterize the current approaches of RRT and other extracorporeal treatments for patients with SARS-CoV-2.
We welcome submissions of Original Research, Case Report, Commentary, Opinion, and Review articles. Specifically, themes of interest include but are not limited to:
• Experimental studies about mechanisms of Covid-19 induced renal damage
• Epidemiology of AKI
• Determination of risk factors for AKI in specific population (chronic haemodialysis, peritoneal dialysis, kidney transplant recipients)
• Extracorporeal therapies protocols for critically ill patients
• Long-term sequelae from COVID-19 infections
